NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status

A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.

NCT Number	NCT07439744
Lead Sponsor	National Science and Technology Council, Taiwan Collaborators: Fondation FondaMental, Fondation pour la Recherche Médicale, Ministry of Science and Technology, Taiwan
Conditions	Obese Adults, MDD
Enrollment	50 participants
Start Date	2025-03-01
Primary Completion	2027-03 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-02-27